Last reviewed · How we verify
3APS
3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.
3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough. Used for Chronic cough (idiopathic pulmonary fibrosis-associated cough), Refractory chronic cough.
At a glance
| Generic name | 3APS |
|---|---|
| Sponsor | Bellus Health Inc. - a GSK company |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
3APS inhibits P2X3 purinergic receptors on vagal sensory neurons, which are involved in the cough reflex pathway. By blocking these receptors, the drug reduces the hypersensitivity of cough-mediating neurons, thereby decreasing cough frequency and severity in patients with chronic cough conditions.
Approved indications
- Chronic cough (idiopathic pulmonary fibrosis-associated cough)
- Refractory chronic cough
Common side effects
- Dysgeusia (taste disturbance)
- Hypogeusia (reduced taste sensation)
- Headache
- Dizziness
Key clinical trials
- European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients (PHASE3)
- Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
- Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3APS CI brief — competitive landscape report
- 3APS updates RSS · CI watch RSS
- Bellus Health Inc. - a GSK company portfolio CI